Stockwinners Market Radar for December 13, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:58 EST Neurocrine announces FDA approval of crenessity - Neurocrine Biosciences announced the U.S. FDA has approved crenessity capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia, a rare, serious and lifelong genetic condition involving the adrenal glands. Crenessity a potent and selective oral corticotropin-releasing factor type 1 receptor antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH.

18:32 EST OFS Credit reports NAV $7.03-$7.13 as of November 30 - OFS Credit Company announced the following net asset value estimate as of November 30. "Management's unaudited estimate of the range of our NAV per share of our common stock as of November 30, 2024 is between $7.03 and $7.13. This estimate is not a comprehensive statement of our financial condition or results for the month ended November 30, 2024. This estimate did not undergo the Company's typical quarter-end financial closing procedures. We advise you that current estimates of our NAV per share may differ materially from future NAV estimates or determinations, including the determination for the period ending January 31, 2025, which will be reported in our monthly report on Form N-PORT."

17:56 EST Checkpoint Therapeutics' unloxcyt approved by FDA - On December 13, the FDA approved cosibelimab-ipdl (unloxcyt), a programmed death ligand-1 blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Reference Link

17:27 EST Checkpoint Therapeutics trading halted, news pending

17:15 EST Lockheed Martin awarded $107.04M Navy contract order - Lockheed Martin was awarded a not-to-exceed $107.04M undefinitized, cost-plus-fixed-fee order against a previously issued basic ordering agreement. This order provides for research and development efforts for trade studies and alternative assessment of all potential power and thermal management solutions, as well as required engine core upgrade block four integration efforts in support of F135 engines upgrades for the F-35 Joint Strike Fighter aircraft for the Air Force, Marine Corps, Navy, Foreign Military Sale customers, and F-35 Cooperative Program Partners. Work is expected to be completed in December 2026. FY24 research, development, test and evaluation funds in the amount of $14.37M; FY24 research, development, test and evaluation funds in the amount of $14.37M and F-35 cooperative program partner funds in the amount of $6.4M, will be obligated at the time of award, $28.74M of which will expire at the end of the current fiscal year. This order was not competed. Naval Air Systems Command is the contracting activity.

16:35 EST Outlook Therapeutics to reduce workforce by 23%, streamline operations - Outlook Therapeutics announced that following an internal strategic review, the management team and board of directors have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing its efforts to commercially launch Lytenava for the treatment of wet AMD in the European Union, or EU, and United Kingdom and supporting the resubmission of the biologics license application, or BLA, for ONS-5010/Lytenava to the FDA. Lytenava has an initial 10 years of market exclusivity. Separately, upon receipt of the full efficacy and safety results for the NORSE EIGHT clinical trial in the United States, which are expected in January 2025, Outlook Therapeutics plans to resubmit its BLA application for ONS-5010 in the first quarter of calendar 2025. Previously, the company announced that ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment with the FDA in the NORSE EIGHT trial. However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010. Lawrence Kenyon, interim CEO and CFO commented, "In light of the current financial market conditions and the Company's strategic focus on the commercial launch of LYTENAVA in Europe, following Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency in the UK, we conducted a strategic review with the goal of preserving capital and extending our cash runway as long as possible. As a result of this process, we identified potential efficiencies and are taking immediate cost-saving measures, including a 23% reduction in our workforce representing $1.4 million in annual savings excluding the costs of the reduction in workforce. As we look ahead, we remain steadfast in our belief in the potential of ONS-5010/LYTENAVA to meet the global needs of retina specialists, patients, and payers and are dedicated to advancing our regulatory and commercial efforts."

16:32 EST Flagstar Financial names Lee Smith as CFO, succeeding Craig Gifford - Flagstar Financial announced the appointment of Lee Smith as Senior Executive Vice President and CFO, effective December 27. The appointment follows the decision of current CFO Craig Gifford to step down to reengage in personal endeavors outside of the banking industry. Gifford will remain with the Bank through March 31, 2025, and work closely with Smith during the transition period, ensuring a seamless hand-over and continued support for the Bank's ongoing initiatives. Smith joined legacy Flagstar Bancorp in 2013 as COO and his transition to CFO comes after serving on Flagstar's executive management team for more than a decade, most recently as President of Mortgage.

16:17 EST Champion Homes names Tim Larson as CEO, succeeding Mark Yost - Champion Homes (SKY) announced the implementation of a succession plan in which Tim Larson, the company's Chief Growth Officer, has been appointed President, CEO, and a member of the Board of Directors, effective immediately. He succeeds Mark Yost in these roles. Yost will be available as needed to support an orderly transition. Larson joined Champion Homes in 2021 as Chief Growth Officer. In this role, he has been responsible for leading the company's direct-to-consumer growth and brand transformation while driving a customer-centric approach to the business. Mr. Larson is an accomplished executive in the consumer products and manufacturing industries, including serving as CEO of Jostens, Inc. and CMO and Sr. Vice President of Global Customer Excellence at Polaris Industries (PII).

16:09 EST Western Digital discloses termination of executive VP and GM Robert Soderbery - Robert Soderbery will cease to serve as executive VP and General Manager, Flash Business, of Western Digital Corporation, effective January 2, 2025, at which time his employment with the company will terminate, according to a regulatory filing. Pursuant to the terms and conditions of the company's amended and restated executive severance plan, the material terms of which have been previously disclose, Soderbery is entitled to receive Tier I severance benefits under the severance plan. Soderbery's receipt of the severance benefits is subject to his non-revocation of a general release of claims.

16:06 EST Western Union announces new $1B share repurchase program - The Western Union Company announced that its Board of Directors approved a new $1B authorization for the company to repurchase its common stock and declared a quarterly cash dividend of 23.5c per common share. The dividend will be payable December 31 to stockholders of record at the close of business on December 23.

16:05 EST Integrated Wellness Acquisition Corp trading halted, news pending

16:02 EST Akamai completes acquisition of certain assets of Edgio - Akamai announced it has completed its acquisition of select assets from Edgio, including certain customer contracts from Edgio's businesses in content delivery and security, and non-exclusive license rights to patents in Edgio's portfolio. On Nov. 26, the U.S. Bankruptcy Court for the District of Delaware approved Akamai's bid to acquire the aforementioned assets following Edgio's 363 bankruptcy auction on Nov. 13, as part of its filing for Chapter 11 bankruptcy relief. The transaction does not include the acquisition of Edgio personnel, technology, or assets related to the Edgio network.

15:05 EST Lamb Weston up 3% as Reuters reports on possible Post deal interest

14:53 EST Insight Acquisition Corp trading resumes

14:29 EST Novartis, pan-Canadian Pharmaceutical Alliance reach agreement for Pluvicto - Novartis Pharmaceuticals Canada announced the "successful conclusion" of negotiations with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Pluvicto. "While this is an important milestone, patients do not yet have public access through provincial and territorial formularies. We look forward to timely collaboration with participating jurisdictions to ensure that eligible prostate cancer patients that are urgently awaiting treatment will have access without further delay," the company stated.

13:18 EST Lavoro Ltd trading halted, volatility trading pause

13:02 EST Porsche sees group result after tax for FY24 'significantly negative'

13:01 EST Baker Hughes reports U.S. rig count unchanged at 589 rigs

12:59 EST Porsche withdraws current forcast for group result after tax for FY24

12:00 EST D-Wave Quantum rises 15.6% - D-Wave Quantum is up 15.6%, or 61c to $4.52.

12:00 EST Finance of America falls -7.0% - Finance of America is down -7.0%, or -$1.79 to $23.89.

12:00 EST Ginkgo Bioworks falls -8.3% - Ginkgo Bioworks is down -8.3%, or -85c to $9.47.

11:41 EST Ackman says short for Robin Hood contest is Icahn Enterprises - In a reply on X discussing his performance in the Robin Hood contest, fund manager Bill Ackman stated: "To clarify, my short for the contest is $IEP. We don't short stocks at Pershing Square." Reference Link

11:35 EST NL Industries trading resumes

11:30 EST NL Industries trading halted, volatility trading pause

11:00 EST Abbott increases quarterly dividend 7.3% to 59c per share - Abbott announced that its board of directors has increased the company's quarterly common dividend to 59c per share, an increase of 7.3%. The company's quarterly dividend payout has increased more than 60% since 2020. The cash dividend is payable Feb. 14, 2025, to shareholders of record at the close of business on Jan. 15, 2025.

10:40 EST CSL receives positive CHMP opinion for garadacimab in HAE - CSL announced the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema in adult and adolescent patients aged 12 years and older. Garadacimab is a monoclonal antibody that targets activated factor XII, a plasma protein that plays a key role in attacks of swelling in people with HAE, thereby inhibiting the HAE cascade at the top to prevent HAE attacks. The final European Commission decision is expected in Q1 2025. The CHMP positive opinion is based on data from the pivotal placebo-controlled Phase 3 VANGUARD trial and its open-label extension study, both evaluating the efficacy and safety of garadacimab. The pivotal study met its primary endpoint and showed that garadacimab led to 62 percent of patients achieving attack-free status throughout the treatment period, reduced the median number of HAE attacks to zero and reduced the mean number of HAE attacks per month by 86.5 percent compared to placebo. Interim analysis of the ongoing open-label extension study showed that garadacimab has a favorable long-term safety profile and provides sustained HAE attack reduction. The full results from VANGUARD were published in The Lancet and the primary results of the ongoing open-label extension study were published in Allergy.

10:02 EST Inno Holdings expands into electronic product trading - Inno Holdings is now developing a new venture in electronic products trading while expanding its sales and distribution network across Asia. Since December 2024, INNO has been undergoing a digital transformation in marketing, distribution and sales. This transformation aims to expand the Company's reach into various electronic products and redefine the landscape of online marketing, sales and distribution.

10:00 EST Direxion Daily Semiconductor Bull 3X Shares rises 9.3% - Direxion Daily Semiconductor Bull 3X Shares is up 9.3%, or $2.66 to $31.12.

10:00 EST RH rises 15.2% - RH is up 15.2%, or $57.86 to $439.24.

10:00 EST X Financial falls -7.4% - X Financial is down -7.4%, or -61c to $7.64.

09:55 EST Swiftmerge Acquisition Corp trading halted, volatility trading pause

09:47 EST Direxion Daily Semiconductor Bull 3X Shares rises 7.4% - Direxion Daily Semiconductor Bull 3X Shares is up 7.4%, or $2.10 to $30.56.

09:47 EST RH rises 17.9% - RH is up 17.9%, or $68.30 to $449.68.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares falls -7.2% - Direxion Daily Semiconductor Bear 3X Shares is down -7.2%, or -$1.65 to $21.19.

09:43 EST Stardust Power Inc trading resumes

09:38 EST Stardust Power Inc trading halted, volatility trading pause

09:16 EST AbbVie to acquire Nimble Therapeutics for $200M cash at closing - AbbVie and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets. Under the terms of the agreement, AbbVie will make a cash payment of $200M at closing to acquire Nimble, subject to certain customary adjustments, in addition to certain interim funding payments. Nimble's shareholders remain eligible for a potential payment, subject to the achievement of a development milestone.

09:06 EST FACT II Acquisition announces separate trading of Class A shares, warrants - FACT II Acquisition announced that, commencing on December 20, 2024, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and warrants included in the Units. The Ordinary Shares and Warrants received from the separated Units will trade on the Nasdaq Global Market under the symbols "FACT" and "FACTW", respectively. Units that are not separated will continue to trade on Nasdaq under the symbol "FACTU". No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. Holders of Units will need to have their brokers contact Odyssey Transfer and Trust Company, the Company's transfer agent, in order to separate the Units into Ordinary Shares and Warrants

09:03 EST MoneyHero announces resignation of CFO - MoneyHero announced the resignation of Hao Qian, the Company's Chief Financial Officer, CFO, effective December 15, 2024. In connection with this development, the Company and its Board of Directors have appointed Danny Leung, MoneyHero's Group Finance Director, to serve as its interim CFO throughout this transitional period.

09:02 EST Viavi to acquire Inertial Labs for initial consideration of $150M at closing - Viavi Solutions announced that it has signed a definitive agreement to acquire Inertial Labs for initial consideration of $150M at closing and up to $175M of contingent consideration over four years. VIAVI intends to fund the transaction through cash on hand. The acquisition is expected to add approximately $50M to VIAVI's Network and Service Enablement annual revenue in calendar year 2025 and is expected to be accretive to EPS within 12 months of closing. The acquisition has been approved by the Board of Directors of each company and is expected to close during the first quarter of calendar year 2025, subject to certain regulatory approvals and customary closing conditions.

08:53 EST Charles Schwab reports November total client assets $10.31T - Charles Schwab released its monthly activity report. Core net new assets brought to the company by new and existing clients totaled $28.8B. Net new assets excluding mutual fund clearing totaled $24.1B. Total client assets equaled $10.31T as of month-end November, up 26% from November 2023 and up 5% compared to October. Transactional sweep cash ended November at $393.7B- or flat versus the prior month. Driven primarily by equity volumes, November daily average trades increased by 20% month-over-month to 6.6M. FY24 net revenue is currently expected to grow by 3% to 3.5% versus the prior year, reflecting a combination of increased investor engagement, post-election equity market strength, and the continued stabilization of client transactional sweep cash balances. This represents an improvement from the 2% to 3% revenue growth range previously communicated.

08:41 EST CMA launches merger inquiry into BlackRock's acquisition of Preqin - The U.K.'s CMA announced the launch of its merger inquiry into the anticipated acquisition by BlackRock of Preqin Limited. The deadline for the CMA to announce its decision whether to refer the Merger for a phase 2 investigation February 12, 2025, the CMA said. Reference Link

08:37 EST Osisko Development provides progress update on Cariboo Gold Project - Osisko Development provides a progress update for its ongoing bulk sample and underground development activities at its 100%-owned Cariboo Gold Project located in central British Columbia, Canada. The Company has now successfully completed 100% of the underground development, totalling approximately 1,172 meters, to access the target area of the contemplated bulk sample in the Lowhee Zone of the deposit. Preparations are underway and in their final stages to extract 10,000 metric tonnes of mineralized material. Stope preparation is largely complete with blasting and extraction expected to be completed in the coming weeks. Results of the bulk sample are anticipated in Q1 2025 supporting ongoing work on the optimized feasibility study expected to be completed in Q2 2025.

08:36 EST VCI Global targets $200M in revenue over next 20 years from solar PV projects - VCI Global is setting a target to develop and acquire up to 100 megawatts of solar photovoltaic projects across Southeast Asia and Europe within the next five years. This expansion is expected to generate approximately $200 million in revenue over the next 20 years and significantly contribute to VCI Global's long-term growth. As part of this initiative, VCI Global plans to source at least 70% of the 100 MW from projects in Malaysia, leveraging key government programs such as the Corporate Renewable Energy Supply Scheme. CRESS allows businesses to directly purchase green electricity from renewable energy developers. Through this initiative, VCI Global will supply renewable energy directly to its data center, further enhancing its energy independence while advancing its sustainability goals. In parallel, VCI Global will seek to acquire solar farms in Eastern and Southeastern Europe, targeting 30 MW of solar capacity in these expanding markets. This international expansion supports the Company's strategy to capitalize on the increasing global demand for clean energy while strengthening its renewable energy portfolio.The total investment required for these solar initiatives is projected to be $50 million over five years, with an expected annual revenue of approximately $10 million over the next 20 years. This sustainable growth strategy will provide long-term, stable returns, reinforcing VCI Global's commitment to clean energy and delivering value to shareholders.

08:32 EST Top Wealth Group announces receipt of Nasdaq notification letter on deficiency - Top Wealth Group announced that it received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on December 9, 2024, indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was below $1.00 per share for 30 consecutive business days.

08:26 EST ChoiceOne Financial, Fentura Financial shareholders approve merger - ChoiceOne Financial Services (COFS) and Fentura Financial (FETM) jointly announced that at separate special meetings held on December 12, each company's shareholders approved the proposed merger in which Fentura will merge with and into ChoiceOne, with ChoiceOne continuing as the surviving corporation. The combined organization will be headquartered in Sparta, Michigan and will operate under the ChoiceOne name and brand following completion of the transaction. The transaction is expected to close in the first quarter of 2025.

08:13 EST Eli Lilly's Omvoh recommended by CHMP for approval in EU - Eli Lilly and Company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Omvoh, an interleukin-23p19 antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. Omvoh was previously approved in the European Union, U.S. and Japan in 2023 as a first-in-class treatment for adults with moderately to severely active ulcerative colitis and is approved in 44 countries around the world. This positive opinion marks the next step toward European regulatory approval of Omvoh for patients with moderately to severely active Crohn's disease, and it is now referred to the European Commission for final action. The European Commission's decision is expected in the next one to two months.

08:12 EST Gryphon Digital Mining mines 17.26 bitcoin in November - November Mining Update: Mined BTC: 17.26439; Total Est. Revenues: $1,487,580 Avg. Price of Mined BTC: $86,165; Total Energy Costs: $1,160,935; Avg. Cost of Mined BTC: $67,244; Total Energy consumed:19,193,491 kWh; Cost per kWh to generate BTC: $0.0605; Margin: $326,647; Margin %: 21.96% Est. Cash on hand at 11/30/24: $545,000; Est. BTC on hand at 11/30/24: 18.367 BTC valued at $1.78M. Steve Gutterman, CEO of Gryphon Digital Mining commented, "We're pleased to release November results and share that December has been a pivotal month for our energy strategy. We have executed what could be a transformative agreement to acquire natural gas assets in British Columbia that could produce low-cost power of 100 MW - 1 GW, and appointed Eric Gallie, a recognized energy industry leader, to coordinate our power initiatives. Eric brings 18 years of energy sector expertise, including managing $1.5 billion in upstream and integrated oil & gas portfolios. We anticipate that his appointment, coupled with our natural gas asset acquisition, positions us to reduce our power costs by more than 50% from current levels of $0.0605/kWh to well under $0.03/kWh. We believe that these strategic moves will fundamentally reshape our energy economics as we scale to meet the growing power demands of both digital mining and AI infrastructure."

08:06 EST Novavax advances growth strategy through partnership with Sanofi - Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50M milestone payment from Sanofi. The $50M milestone is the first following the initial upfront payment at signing of the agreement with Sanofi in May 2024. Following this payment, there are additional potential milestones of up to $300M related to Novavax's partnered COVID-19 vaccine that will be recognized in the periods when earned. In addition to milestones for the stand-alone COVID-19 vaccine, the agreement also includes combination products developed by Sanofi including Novavax's COVID-19 vaccine, which present a potential opportunity of up to an additional $350M for Novavax in future milestones. In addition, both stand-alone COVID-19 sales and potential sales of any Sanofi combination products would net Novavax ongoing tiered royalties. Further, Novavax is eligible to receive up to $200M for the first four products created by Sanofi utilizing its Matrix-M adjuvant, and up to $210M in milestone payments for each product including Matrix-M thereafter, plus ongoing royalties for all Sanofi products utilizing Matrix-M.

08:04 EST Southern Realty Trust originates $57M senior loan for The Loren - Southern Realty Trust originated a senior loan in the aggregate amount of $57.0 million for the refinancing of The Loren at Lady Bird Lake, a luxury hotel located in Austin, Texas. The Sponsor is The Loren Group. SRT holds $25.0 million of the loan, while the remaining $32.0 million was syndicated to an affiliate on the TCG Real Estate platform. JLL Capital Market's Debt Advisory team representing the borrower was led by Wally Reid and Scott Dickey.

08:03 EST Sunrise Realty Trust commites $32M in senior loan for The Loren - Sunrise Realty Trust has committed $32.0 million, of which the Company funded $29.9 million, to a $57.0 million senior loan originated by an affiliate on the TCG Real Estate platform. This loan is for the refinancing of The Loren at Lady Bird Lake, a luxury boutique hotel located in Austin, Texas. The Sponsor is The Loren Group, a leading real estate company that specializes in developing, owning, and managing luxury hotels in high-demand destination markets. JLL Capital Market's Debt Advisory team representing the borrower was led by Wally Reid and Scott Dickey. The Loren is a 108-key boutique luxury hotel at 1211 W Riverside Drive, part of a mixed-use project that includes 24 condominiums, two restaurants, a spa, fitness center, rooftop terrace with an infinity pool, and event space with sweeping lake and city views. Situated on a prime 1.5-acre site along the south bank of Lady Bird Lake, the Project offers a tranquil retreat while remaining within easy reach of downtown Austin's top attractions, including Zilker Park and the South Congress district. This location provides guests with unmatched access to the heart of Austin's cultural and recreational offerings, combining luxury, convenience, and scenic surroundings in one destination.

07:57 EST BriaCell announces presentation on BRIA-IMT regimen in metastatic breast cancer - BriaCell Therapeutics highlights the infiltration of cancer fighting immune cells into tumors, using leading CD8 ImmunoPET imaging technology, in its poster presentation at the 2024 San Antonio Breast Cancer Symposium at Henry B. Gonzalez Convention Center, San Antonio, TX. Today's poster shows influx of cancer fighting immune cells into tumors and lymphatic tissue leading to cancer cell destruction following treatment with the Bria-IMT plus CPI regimen. BriaCell employed this advanced imaging technology as a precision diagnostic tool to monitor patients' immune system responses in its phase 2 study, establishing the ability of the Bria-IMT regimen to induce tumor infiltration with CD8+ "killer" T cells. These results suggest a potential value of CD8 ImmunoPET in identifying pseudo progression in patients with clinical benefit vs tumor progression. CD8+ T cell infiltration also correlated with a marked reduction in tumor markers, indicating clinical benefit, in some patients. Title: Bria-IMT CD8+ tumor infiltrating lymphocytes turn "Cold" tumor "Hot" in metastatic breast cancer: CD8 ImmunoPET imaging, an imaging analysis technology, is used to mark CD8+ T-cells that are important components of the immune system and key to cancer cell detection and destruction. Bria-IMT plus CPI produced cancer-fighting CD8+ T cells infiltration into metastatic tumors and lymphoid tissue, leading to cancer destruction - turning "Cold" tumors and lymph nodes "Hot" on ImmunoPET imaging Using metastatic site-specific CD8+ PET imaging technology, BriaCell reports the following in 6 patients treated with Bria-IMT plus CPI after 9 cycles of treatment: Treatment generally well tolerated; Reduction in tumor markers in 2 patients who had cold tumors turn hot; 3 out of the 6 patients showed a decrease in neutrophil/lymphocyte ratio at cycle 2 when compared to baseline values suggesting immune system activation of the patients; Evidence of "cold" tumors and lymph nodes becoming "hot" suggesting immune system activation in the patients; Immune system activation results in increased migration of cancer-fighting CD8+ T-cells into MBC tumors and lymphatic tissue, leading to destruction of cancer cells; Immune response following peripheral non-lesional Bria-IMT therapy suggests systemic activation of the immune system; Clinical and CD8+ T cell response support the clinical benefit of the Bria-IMT plus CPI regimen in cancer patients. In summary, advanced ImmunoPET imaging technology correlates with clinical benefit with the Bria-IMT combination regimen in metastatic breast cancer and suggests possible use in identifying immunotherapy responsive tumors. These findings support the continued use of the Bria-IMT combination regimen in BriaCell's ongoing pivotal Phase 3 study in MBC.

07:31 EST Zimmer Biomet receives FDA clearance for OsseoFit Stemless Shoulder System - Zimmer Biomet announced U.S. FDA 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy1-3 to optimize anatomical fit while maximizing preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio and integrates with Identity Humeral Heads with Versa-Dial Technology for infinite offset placement as well as the Alliance Glenoid for a broad range of glenoid options to adapt to a patient's unique anatomy.

07:16 EST Farmland Partners declares $1.15 per share special cash dividend - Farmland Partners announced that its board of directors has declared a one-time dividend of $1.15 per share of common stock and Class A Common OP Unit, payable in cash on January 8, 2025 to shareholders of record on December 23.

07:07 EST Guardian Capital renews normal course issuer bid - Guardian Capital has received approval from the Toronto Stock Exchange for its Normal Course Issuer Bid, pursuant to which it intends to purchase, during the period from December 19, 2024 to December 18, 2025, up to 136,918 or 5% of its outstanding Common Shares, entitled to one vote per share, and up to 1,507,908 or 10% of its public float of Non-Voting Class A Shares as at December 5, 2024. Shares may also be purchased by the trustee for Guardian's employee profit sharing plan, which purchases will count against the maximum numbers of shares which may be purchased by Guardian. In each case, these shares will be purchased at market prices, on the TSX, other designated exchanges and/or alternative Canadian trading systems. All shares purchased by Guardian will be cancelled. Guardian intends to purchase the shares because it believes that, from time to time, the shares may become undervalued at prevailing market prices, based on Guardian's earnings and prospects and accordingly, Guardian is of the opinion that the purchase of shares for cancellation is an appropriate use of corporate funds to increase shareholder value. Pursuant to its current Normal Course Issuer Bid, under which Guardian sought and received approval from the TSX to purchase up to 136,918 Common Shares and 1,545,132 Class A Shares for the period from December 19, 2023 to December 18, 2024, Guardian and the Trustee have purchased, as of December 5, 2024, 0 Common Shares and 609,989 Class A Shares at an average purchase price of $44.17 per Class A Share. These shares were purchased on the TSX and alternative Canadian trading systems.

07:03 EST Ocular Therapeutix reports inducement grant under Nasdaq listing rule - Ocular Therapeutix has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of December 9, 2024 and consist of non-statutory stock options to purchase up to 215,000 shares of Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on the effective date of grant, and restricted stock unit awards representing the right to receive 70,000 shares of Ocular's common stock. The stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of the recipient's employment commencement date and the remainder vesting in equal monthly installments over the three years thereafter, subject to the individual's continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal annual installments, beginning on December 9, 2024, and subject to the recipient's continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular's 2019 Inducement Stock Incentive Plan.

07:01 EST Monte Rosa Therapeutics appoints Hughes to board of directors - Monte Rosa Therapeutics (GLUE) announced the appointment of Eric Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical (TEVA)

07:00 EST Roche receives CE Mark for new, updated molecular cobs 6800/8800 systems - Roche announced the CE certification of the new cobas 6800/8800 systems 2.0. The update significantly enhances the efficiency of laboratories by optimizing resources, reducing downtime, consolidating test menus, and increasing throughput. These improvements promise a more streamlined diagnostics experience for healthcare professionals and their patients. Laboratories can now perform a wider range of tests on a single solution, simplifying laboratory logistics and helping to optimize the use of resources.

06:46 EST Invitation Homes raises quarterly dividend to 29c from 28c per share - Invitation Homes announced that its board of directors has declared a regular quarterly cash dividend of 29c per share payable on shares of its common stock, representing a 3.6% increase over the prior quarterly dividend of 28c per share. The dividend will be paid on or before January 17, 2025, to stockholders of record of the company's common stock as of the close of business on December 26, 2024.

06:38 EST Geron announces positive CHMP opinion for Rytelo - Geron announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission, which has the authority to approve medicines in the European Union, will review the CHMP's recommendation and is expected to make a final decision on the marketing authorization application in the following months.

06:05 EST KeyCorp, Scotiabank receive regulatory approval to complete investment - KeyCorp (KEY) announced that all required regulatory approvals have been received for completion of The Bank of Nova Scotia's, or Scotiabank (BNS), strategic minority investment in Key as announced on August 12. The board of governors of the Federal Reserve System approved the approximately 10% remaining investment by Scotiabank, which is expected to close in 2024. The initial investment of 4.9% was completed on August 30.

06:03 EST Joby Aviation successfully completes series of flight tests in Korea - Joby Aviation announced it has successfully completed a series of flight tests in Korea as part of the K-UAM Grand Challenge. Joby is the first electric air taxi company to complete flights as part of the program, which was launched in 2023 by Korea's Ministry of Land, Infrastructure and Transport to support the commercialization of air taxis in the Korean market.

05:23 EST Electronic Arts, Hazelight Studios reveal 'Split Fiction' - Electronic Arts and Hazelight Studios revealed "Split Fiction", an action-adventure game. Developed by Hazelight Studios, comes a co-op action-adventure split screen game where players will jump between sci-fi and fantasy worlds. With a wide range of abilities, players will take on the roles of Mio and Zoe as they work together to take back their creative legacies and discover the power of an unexpected friendship.

05:16 EST AirNet Technology co-CEO Fuying Yan resigns, Yuan Feng to succeed - AirNet Technology announced changes in its senior management team. Each of Fuying Yan and Tong Lin has tendered resignation as a director of the company, effective from December 13. The company said their resignation was for personal reasons and did not result from any disagreement with the company on any matter relating to the company's operations, policies or practice. In addition, Fuying Yan has also tendered resignation as the co-chief executive officer of the company for personal reasons, effective from the same date. Yuan Feng has been appointed as the company's co-chief executive officer and director of the board, effective from December 13. Yanxiao Zhu has been appointed as an independent director of the board, effective from the same date. Upon the effectiveness of the above-mentioned changes, the board will consist of five directors, including three independent directors. Yuan Feng had served as a deputy director of European and American business department at Huayou New Energy Technology from October 2021 to December.

04:52 EST EVgo announces closing of $1.25B Department of Energy loan - EVgo announced the closing of its $1.25B guaranteed loan facility from the Department of Energy Loan Programs Office under its Title 17 Clean Energy Financing Program to support EVgo's forthcoming efforts to build public charging infrastructure for electric vehicles with the construction of 7,500 new fast charging stalls nationwide. "This buildout will bring EVgo's total owned and operated network to at least 10,000 fast charging stalls, allowing the Company to more than triple its network footprint by 2029," the company said in a statement. EVgo estimates this project buildout will create more than 1,000 jobs in the U.S., over 700 of which will be contracted resources engaged by the company encompassing roles in construction, engineering, development, and operations and maintenance.